Page 94 - GTM-3-4

Global Translational Medicine Blood parameters for SCLC and AC relapse prognosis

Table 8. Diagnostic significance of determining low and high risk of recurrence of AC (ROC analysis data)
Indicator TV SE SP PPV NPV AUC ACC
CXCR1, lymphocytes, % >2.55 66.2 84.4 81.8 70.1 0.715 75.3
CYFRA 21-1, ng/mL >4.16 71.4 74.0 75.3 70.1 0.709 72.7
Monocytes, ×10 /L >0.77 66.2 63.6 66.2 63.6 0.627 64.9
9
9
Eosinophilic leukocytes, ×10 /L >0.24 62.3 74.0 72.7 63.6 0.651 67.5
Eosinophilic leukocytes/Monocytes >0.313 76.6 63.6 70.1 70.1 0.673 70.1
Z >0.597 85.7 94.8 89.6 84.4 0.841 89.0
Abbreviations: TV: Threshold value; SE: Sensitivity; SP: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; AUC: Area under
ROC-curve; ACC: Accuracy; CXCR1: C-X-C motif chemokine receptor 1; CYFRA 21-1: Cytokeratin 19 fragment antigen 21-1.

AQ2 Figure 1. Relapse-free survival of patients with Stage III squamous cell the obtained threshold value Z = 0.597, is demonstrated
lung cancer (A and B) and adenocarcinoma (C and D), stratified by the by the Kaplan-Meier graph of the survival of patients with
TNM classifications over the course of 12 months after the treatment. Stage III AC before progression (Figure 3).
Figure 2. Relapse-free survival of patients with Stage III squamous cell
lung cancer according to the results of the regression equation Y The analysis of the quality of the logistic regression
Figure 3. Relapse-free survival of patients with Stage III adenocarcinoma equation (2) shows that all the selected indicators make
according to the results of the regression equation Z
a significant contribution. This is demonstrated by the
significant decrease in the negative doubled value of the
logarithm of the likelihood function (Δ = 35.1, P < 0.05),
indicating the good quality of the proposed model. This is
also evidenced by the Hosmer–Lemeshev goodness-of-fit
criterion, which was calculated to be 12.1 (P = 0.158).
The P > 0.05 confirms the consistency of the regression
equation in classifying patients as having low or high risks
of tumor occurrence in AC.
Figure 3. Relapse-free survival of patients with Stage III adenocarcinoma
4. Discussion according to the results of the regression equation Z.
The prognosis for patients with Stage III (T1-4N0-2)
NSCLC remains poor, with their overall five-year survival It is evident that to obtain such information, cohort
after treatment varying and the median not exceeding studies focusing on patients with relatively homogeneous
20 months. It is vital to anticipate disease progression, not characteristics and individual histological subtypes of
1-3
only to save time but also to reduce treatment expenditures NSCLC are required. The scarcity of information on
by switching to alternative therapeutic strategies. One of biomarkers prompted us to conduct our own retrospective
2,15
the approaches to optimizing the effectiveness of treatment and prospective study involving patients with Stage III (T1-
in this category of patients is the ability to predict those at 4N0-2) SCLC and AC. Based on the pathogenesis of these
high risk of relapse. Despite the relevance and motivation tumors, we decided to investigate blood cells parameters
of researchers, prognostic markers of NSCLC remain and proteins, including the CXCR1 and CXCR2 receptors,
controversial. As has been demonstrated, the impacts of as well as their ligands, the proinflammatory cytokines
these prognostic markers are influenced by the histological CXCL5 and CXCL8.
type of the tumor, the disease stage, and the treatment
regimen employed. 17-19,22 However, there is no information First, Kaplan-Meier survival analysis of the results from
regarding the use of prognostic markers for patients with one year of retrospective observation showed a significant
Stage III NSCLC, specifically for the two main histological difference in relapse-free survival between patients with
types: AC and SCLC. tumor descriptors T4N1M0 and T4N2M0 in SCLC and AC
(high risk of recurrence) and those with other combination
Nevertheless, most researchers have observed a of TNM descriptors (T1N2M0, T3N1M0, T2N2M0,
correlation between the concentration of CYFRA 21-1 in T4N0M0, and T3N2M0) (low risk of recurrence).
blood serum and both relapse-free and overall survival in
patients with advanced stages of NSCLC. However, these Then, the results of the TNM stratification were used
studies analyzed a mixed cohorts in terms of the disease in the study group to compare the levels of 42 detectable
stage, including patients at early stages of the disease. 3,9,10 laboratory parameters between patients with high and low

Volume 3 Issue 4 (2024) 10 doi: 10.36922/gtm.4865